Could a Two-Vaccine strategy better shield spleenless patients from pneumonia?
NCT ID NCT03873727
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This trial investigates whether giving two different pneumonia vaccines—one followed by another a year later—boosts immune protection more than a single vaccine alone in adults who have had their spleen removed. People without a spleen are at higher risk for serious pneumococcal infections. The study compares a combined vaccine approach against the standard single vaccine, measuring antibody responses in blood samples.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Prevenar13 (PCV13) and Pneumovax (PPS23) vaccines
- What this could lead to
- If successful, this could establish a more effective revaccination schedule to better protect splenectomised patients from serious pneumococcal infections.
- What could go wrong
- This is a Phase 2 trial with only 39 participants, so results may not apply to all patients. The immune response measured may not translate to real-world infection prevention.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPLENECTOMISED PATIENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CIC 1417 Cochin-Pasteur - GH Broca-Cochin-Hôtel-Dieu
Paris, 75014, France